ORLY
58
8
EXR
44
4
HPQ
37
6
PH
60
-2
CI
45
2
AMT
39
3
MDLZ
34
4
MAC
53
2
GME
55
3
PEP
56
3
HSY
53
3
HP
36
2
DOW
62
2
FRT
45
2
CAT
55
-2
MUR
49
2
COF
47
-3
ESS
33
2
PNW
69
2
TXT
70
-2
ORLY
58
8
EXR
44
4
HPQ
37
6
PH
60
-2
CI
45
2
AMT
39
3
MDLZ
34
4
MAC
53
2
GME
55
3
PEP
56
3
HSY
53
3
HP
36
2
DOW
62
2
FRT
45
2
CAT
55
-2
MUR
49
2
COF
47
-3
ESS
33
2
PNW
69
2
TXT
70
-2
Financhill
Back

DeNA Co., Ltd. 10K Form

Sell
44

DNACF
DeNA Co., Ltd.

Last Price:
$18.16
Seasonality Move:
-0.52%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive DNACF News And Ratings

See the #1 stock for the next 7 days that we like better than DNACF

DNACF Financial Statistics

Sales & Book Value

Annual Sales: $1.1B
Cash Flow: $40.3M
Price / Cash Flow: 8.48
Annual Sales: $14.39
Price / Book: 1.26

Profitability

EPS (TTM): 1.54590
Net Income (TTM): $166.6M
Gross Margin: $599M
Return on Equity: 9.55%
Return on Assets: 6.48%

DeNA Co., Ltd. Earnings Forecast

Key DeNA Co., Ltd. Financial Ratios

  • The Gross Profit Margin over the past 23 years for DNACF is 55.68%.
  • The Selling, General & Administrative Expenses for DNACF have been equal to 36.10% of Gross Profit Margin.
  • The Research & Development expenses have been 0.40% of Revenue.
  • The Interest Expense is 1.19% of Operating Income.
  • The Net Earning history of DNACF is 14.00% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 14 years.

DeNA Co., Ltd. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Entertainment
Sector: Communication Services
Current Symbol: DNACF
Website: dena.com/jp/

Debt

Debt-to-Equity Ratio: 0.19
Current Ratio: 1.96
Quick Ratio: 1.87

Price-to-Earnings

Trailing P/E Ratio: 12.76
Forward P/E Ratio: 0

DNACF Technical Analysis vs Fundamental Analysis

Sell
44
DeNA Co., Ltd. (DNACF) is a Sell

Is DeNA Co., Ltd. a Buy or a Sell?

  • DeNA Co., Ltd. stock is rated a Sell
    The current DeNA Co., Ltd. [DNACF] share price is $18.16. The Score for DNACF is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.